IRIDICA Observational Study - Sepsis

• Research type

  Research Study

• Full title

  An observational study to analyze the impact of Polymerase Chain Reaction/Electrospray Ionization – Mass Spectrometry (PCR/ESI-MS) [IRIDICA] intervention in patients in ICU, or pending ICU admission, with sepsis, compared to historical control data.

• IRAS ID

  201873

• Contact name

  Paul Dark

• Contact email

  paul.m.dark@manchester.ac.uk

• Sponsor organisation

  Abbott Laboratories

• Duration of Study in the UK

  0 years, 6 months, 31 days

• Research summary

  The objective of this study is to analyze the impact on clinical and economic outcomes of Polymerase Chain Reaction/Electrospray Ionization – Mass Spectrometry (PCR/ESI-MS) [IRIDICA] when incorporated into the standard of care of patients with sepsis being admitted to the critical care unit as compared to historical control data.

• REC name

  Wales REC 4

• REC reference

  16/WA/0107

• Date of REC Opinion

  6 May 2016

• REC opinion

  Further Information Favourable Opinion